Literature DB >> 23712072

Vitamin D status in patients with recurrent kidney stones.

Chrysoula Pipili1, Dimitrios G Oreopoulos.   

Abstract

Data regarding the prevalence of 25-hydroxyvitamin D (25(OH)D) insufficiency in patients with nephrolithiasis, and the effects of vitamin D supplementation on parathyroid hormone (PTH) are few and conflicting. In this article, we examined the prevalence of vitamin D insufficiency and deficiency in 236 recurrent kidney stone formers and the correlation of vitamin D levels with other parameters of stone formation. The prevalent stone composition was calcium oxalate (80.4%) and uric acid (16.45%). One third of stone formers had vitamin D insufficiency and a quarter of them high PTH levels (PTH >7.5 pmol/l) with normal serum (total and ionized) calcium values. Predictor of high PTH was low 25(OH)D level (r = 0.989, r(2) = 0.977, p < 0.001). Stone formers with hypercalciuria had higher 25(OH)D values (72.26 ± 4.21 vs. 59.29 ± 1.76, p = 0.0013) compared to stone formers with urine calcium within normal ranges. Further studies are needed in order to better define the consequences of vitamin D insufficiency and to evaluate the impact of the therapeutic interventions in this cohort.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23712072     DOI: 10.1159/000351377

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  11 in total

1.  CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update.

Authors:  Marie Dion; Ghada Ankawi; Ben Chew; Ryan Paterson; Nabil Sultan; Patti Hoddinott; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

Review 2.  Pathogenesis of calcium oxalate urinary stone disease: species comparison of humans, dogs, and cats.

Authors:  Allison L O'Kell; David C Grant; Saeed R Khan
Journal:  Urolithiasis       Date:  2017-03-30       Impact factor: 3.436

Review 3.  Environmental and stressful factors affecting the occurrence of kidney stones and the kidney colic.

Authors:  Rigas G Kalaitzidis; Dimitrios Damigos; Kostas C Siamopoulos
Journal:  Int Urol Nephrol       Date:  2014-06-14       Impact factor: 2.370

4.  UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.

Authors:  Naeem Bhojani; Jennifer Bjazevic; Brendan Wallace; Linda Lee; Kamaljot S Kaler; Marie Dion; Andrea Cowan; Nabil Sultan; Ben H Chew; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

5.  Analysis of vitamin D deficiency in calcium stone-forming patients.

Authors:  María Sierra Girón-Prieto; María Del Carmen Cano-García; Miguel Ángel Arrabal-Polo; Antonio Poyatos-Andujar; Miguel Quesada-Charneco; Tomás de Haro-Muñoz; Salvador Arias-Santiago; Miguel Arrabal-Martín
Journal:  Int Urol Nephrol       Date:  2016-04-19       Impact factor: 2.370

6.  Prevalence of Vitamin D Inadequacy in Urolithiasis Patients.

Authors:  Kunal Dholakia; Nivash Selvaraj; Narasimhan Ragavan
Journal:  Cureus       Date:  2021-06-01

7.  Effect of vitamin D supplementation on 24-hour urine calcium in patients with calcium Urolithiasis and vitamin D deficiency.

Authors:  Maryam Taheri; Sanaz Tavasoli; Fatemeh Shokrzadeh; Fahimeh Bagheri Amiri; Abbas Basiri
Journal:  Int Braz J Urol       Date:  2019 Mar-Apr       Impact factor: 1.541

8.  Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance.

Authors:  Vybhav Jetty; Charles J Glueck; Ping Wang; Parth Shah; Marloe Prince; Kevin Lee; Michael Goldenberg; Ashwin Kumar
Journal:  N Am J Med Sci       Date:  2016-03

9.  Seasonal variations in urinary calcium, volume, and vitamin d in kidney stone formers.

Authors:  Kyrollis Attalla; Shubha De; Carl Sarkissian; Manoj Monga
Journal:  Int Braz J Urol       Date:  2018 Sep-Oct       Impact factor: 1.541

10.  [Hyperparathyroidism in patients with stones. Influence of deficit 25-OH vitamin D].

Authors:  Miguel Ángel Arrabal-Polo; María Del Carmen Cano-García; María Sierra Girón-Prieto; Miguel Arrabal-Martín
Journal:  Aten Primaria       Date:  2016-01-28       Impact factor: 1.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.